Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 3, 2010, Pages 256-262

  Brochot, Anne ^a   Zamacona, Miren ^b   Stockis, Armel ^a  

^a UCB PHARMA   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; BRIVARACETAM; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUDIOGENIC SEIZURE; BRAIN TISSUE; CONCENTRATION RESPONSE; CONFERENCE PAPER; DISEASE SIMULATION; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; EX VIVO STUDY; EXPERIMENTAL MODEL; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SYNAPSE VESICLE;

ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; HUMANS; LOGISTIC MODELS; MEMBRANE GLYCOPROTEINS; MICE; NERVE TISSUE PROTEINS; PHARMACOLOGY; PHYSIOLOGY; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; PYRROLIDINONES; TISSUE DISTRIBUTION;

ANIMALIA; BREDA VIRUS; MUS;

EID: 77149121089     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00536.x     Document Type: Conference Paper

References (13)

1. Kwan P, Brodie MJ. Emerging drugs for epilepsy. Expert Opin Emerg Drugs 2007 12 : 407 422.
2. von Rosenstiel P, Perucca E. Brivaracetam. In : Shorvon S, Perucca E, Engel J (eds). The Treatment of Epilepsy, 3rd edn. Wiley-Blackwell, Hoboken, NJ, 2009 421 431.
3. Kaminski RM, Gillard M, Leclercq K, Hanon E, Lorent G, Dassesse D et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009 50 : 1729 1740.
4. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008 154 : 1662 1671.
5. Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br J Clin Pharmacol 2008 66 : 71 5.
6. Sargentini-Maier ML, Espié P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Disp 2008 36 : 36 45.
7. Kasteleijn-Nolst Trenité D, Parain D, Masnou P, Genton P, Steinhoff B, Jacobs T et al. Proof of principle for the new antiepileptic drug brivaracetam: use of the photosensitivity model. Neurology 2007 69 : 1027 1034.
8. Laveille C, Lacroix B, Snoeck E, Sargentini-Maier ML, von Rosenstiel P, Stockis A. Dose- and exposure-response modeling of brivaracetam add-on treatment in patients with partial epilepsy. Epilepsia 2007 48 (Suppl. 6 328.
9. Gillard M, Fuks B, Michel P, Vertongen P, Massingham R, Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol 2003 478 : 1 9.
10. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006 95 : 1238 1257. Erratum in: J Pharm Sci 2007;96:3153-4.
11. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of non-specific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties. Drug Metab Dispos 2002 30 : 1497 1501.
12. Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values. Ann ICRP 2002 32 : 1 277.
13. Hammarlund-Udenaes M, Paalzow LK, de Lange ECM. Drug equilibration across the blood-brain barrier. Pharmacokinetic considerations based on the microdialysis method. Pharm Res 1997 14 : 128 134.